Dirk Eyding

Dirk Eyding is a Clinical Science Director at Pharmacosmos since March 2023, with extensive experience in clinical research and health policy. Previous roles include Scientist with Paula Piechotta in October 2022, Senior Consultant at Medizinischer Dienst Bund from January 2018 to September 2022, and Head of Innovation Assessment at Medizinischer Dienst des Spitzenverbandes Bund der Krankenkassen e.V. from November 2011 to July 2017. Dirk's expertise encompasses HTA reports on medical interventions, conducting clinical trials in oncology with the Deutsche Krebsgesellschaft, and managing clinical studies at Lundbeck and PAION AG. Academic credentials include an M.Sc. in Pharmaceutical Medicine from the University of Duisburg-Essen, a PhD in Neuroscience from Ruhr University Bochum, and a Master of Science in Biology from The Julius Maximilians University of Würzburg.